OpenBiome is announcing a collaboration with the University of Minnesota’s Microbiota Therapeutics Program to ensure that patients with recurrent C. difficile infections have access to fecal microbiota transplantation (FMT) until an FDA-approved alte
According to the CDC, C. difficile is a bacterium that causes severe diarrhea and colitis. It’s estimated to cause almost half a million infections in the U.S. each year. About one in six patients who get C. difficile will get it again in the subsequent 2-8 weeks. One in eleven people over age 65 diagnosed with a healthcare-associated C. difficile infection die within one month.